The Global Neurodegeneration Proteomics Consortium (GNPC) has released research analyses of one of the world’s largest protein datasets in order offer new insights into the biological underpinnings of major neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.

The findings, published in a series of papers in Nature Medicine, reveal unique protein biomarkers that correlate with neurodegenerative diseases and the ageing process, and may help with the early detection, and improve outcomes, of major neurodegenerative diseases.

Neurodegenerative diseases pose a growing global health challenge, affecting over 57 million people globally, with numbers projected to double every 20 years. However, the search for effective treatments has been hindered by diagnostic challenges and a poor understanding of disease mechanisms.

Biomarkers can help clinicians identify and diagnose neurodegenerative diseases earlier and produce better treatments, but challenges in assembling large, diverse datasets for these analyses have slowed progress. By leveraging advanced technologies to study proteins, researchers have started to unravel the complex molecular landscape of neurodegeneration, offering hope for earlier diagnosis and more-targeted therapies.

Research data and findings

In the paper, Farhad Imam and colleagues from the GNPC present one of the largest proteomic datasets, including approximately 250 million unique protein measurements from over 35,000 biofluid samples, such as blood plasma and cerebrospinal fluid. These samples were provided by 23 research communities globally and include associated clinical data. From this, the authors identified specific proteins associated with Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and amyotrophic lateral sclerosis.

Three associated papers from the GNPC, also published in Nature Medicine, demonstrate how analyses of this dataset can be applied to address key questions in neurodegenerative disease and ageing research. Carlos Cruchaga and colleagues identified disease-specific plasma biomarker profiles and a protein signature across Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, and revealed distinct and shared mechanisms, highlighting potential regulatory proteins and pathways for diagnostic and therapeutic strategies. Catilin Finney, Artur Shvetcov and colleagues identified a plasma protein signature associated with carriers of the allele encoding APOE ε4 allele, a genotype known to increase the risk of Alzheimer’s disease, and suggest that this molecule has a broader role in neurodegeneration. Tony Wyss-Coray and colleagues identified age-related changes in proteins that correlate with cognitive function, offering new insights into how changes in protein levels in the cerebrospinal fluid and plasma are associated with cognitive health.

The authors highlight the importance of international collaboration, data sharing and using diverse datasets to accelerate discovery in neurodegeneration research. Future research with more diverse populations aims to develop new ways to diagnose, prevent, and treat neurodegenerative diseases, driving advances towards better outcomes through precision, combination therapy optimised for a patient’s disease subtypes.

Megan Thomas, Multimedia Editor, DDW